<DOC>
	<DOCNO>NCT00036855</DOCNO>
	<brief_summary>Phase I trial study effectiveness radiolabeled monoclonal antibody therapy without peripheral stem cell transplantation treat patient recurrent refractory lymphoma . Radiolabeled monoclonal antibody locate cancer cell deliver radioactive tumor-killing substance without harm normal cell . Peripheral stem cell transplantation may able replace immune cell destroy anticancer therapy</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody With Without Peripheral Stem Cell Transplantation Treating Children With Recurrent Refractory Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) yttrium Y 90 ibritumomab tiuxetan ( IDEC-Y2B8 ) precede rituximab child recurrent refractory CD20-positive lymphoma autologous peripheral blood stem cell transplantation ( AuPBSCT ) plan . ( Group A ) If dose-limiting toxicity ( DLT ) group A purely hematological , determine MTD IDEC-Y2B8 combine rituximab , AuPBSCT , filgrastim ( G-CSF ) second group child recurrent refractory CD20-positive lymphoma . ( Group B ) II . Determine DLT rituximab IDEC-Y2B8 patient . III . Determine dosimetry indium In 111 ibritumomab tiuxetan precede rituximab patient . IV . Determine , preliminarily , antitumor activity rituximab IDEC-Y2B8 patient . V. Assess immune cell depletion ( B-cell T-cell ) recovery patient treat regimen . VI . Determine human anti-mouse antibody response patient treat regimen . OUTLINE : This multicenter , dose-escalation study yttrium Y 90 ibritumomab tiuxetan ( IDEC-Y2B8 ) . Patients assign 1 2 group . GROUP A ( plan peripheral blood stem cell [ PBSC ] support ) : Patients receive rituximab IV 4-6 hour follow indium In 111 ibritumomab tiuxetan ( IDEC-In2B8 ) IV 10 minute day 0 undergo whole body image . Patients may receive rituximab IV 4-6 hour follow IDEC-Y2B8 IV 10 minute day 7 . Cohorts 3-6 patient subgroup ( A1 , A2 , A3 ) receive escalate dos IDEC-Y2B8 maximum tolerate dose ( MTD ) determine ( subgroup A1 close 10/8/04 ) . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity ( DLT ) . Some patient receive autologous PBSC IV 30-60 minute day 35 . GROUP B ( plan PBSC support ) : Patients receive rituximab , IDEC-In2B8 , IDEC-Y2B8 group A . Patients also receive autologous PBSC IV 30-60 minute day 21 filgrastim ( G-CSF ) subcutaneously begin day 22 continue blood count recover day 35 . If DLT group A purely hematological , cohort 3-6 patient group B receive escalate dos IDEC-Y2B8 MTD determine . The MTD define group A . Patients group follow day 63 , 90 , 180 , 365 , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm immunophenotypically ( CD20 ) positive lymphoma original diagnosis , progression , relapse Refractory conventional therapy First recurrent/refractory CD20positive nonHodgkin 's lymphoma ( NHL ) allow ineligible refused regimen know curative potential ( highdose chemotherapy plus bone marrow transplantation ) ( available ) Second third progression and/or recurrence NHL Second third relapse/refractory CD20positive Hodgkin 's lymphoma CD20positive , posttransplantation lymphoproliferative lymphoma medically refractory ( decreased immunosuppression ) rituximab and/or chemotherapy Medically refractory , HIVassociated , CD20positive NHL Recurrent/refractory CD20positive lymphoblastic lymphoma Autologous peripheral blood stem cell ( PBSC ) collect , select minimum 2 x 10^6 CD34positive cell per kg , cryopreserved study entry Meets one follow criterion bone marrow reserve : Good marrow reserve , define follow : No prior myeloablative stem cell transplantation ( SCT ) No prior extensive radiotherapy , define following : Prior total body irradiation Prior radiotherapy dose 3,600 cGy craniospinal axis Prior radiotherapy 50 % bone marrow Poor marrow reserve , define either follow : Prior myeloablative SCT Prior extensive radiotherapy Performance status Lansky 50100 % ( age 10 ) Performance status Karnofsky 50100 % ( age 11 21 ) At least 2 month Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 patient poor marrow reserve ( transfusion independent ) Platelet count ≥ 150,000 patient good marrow reserve ( transfusion independent ) Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 5 time ULN Albumin ≥ 2 g/dL Creatinine normal Creatinine clearance glomerular filtration rate ≥ 70 mL/min Shortening fraction ≥ 27 % echocardiogram Ejection fraction ≥ 50 % MUGA No dyspnea rest No exercise intolerance Oxygen saturation ( SpO_2 ) &gt; 94 % pulse oximetry ( clinical indication SpO_2 assessment ) Not pregnant nursing Negative pregnancy test No document infection unresponsive appropriate antibiotic , antiviral , antifungal therapy No grade 2 great CNS toxicity Seizure disorder allow well controlled anticonvulsant See Disease Characteristics Recovered prior immunotherapy At least 1 week since prior antineoplastic biologic agent Prior SCT allow follow criterion meet : At least 60 day since prior SCT Full hematopoietic reconstitution postSCT No evidence active acute chronic graftversushost disease post allogeneic SCT No concurrent sargramostim ( GMCSF ) See Disease Characteristics At least 3 week since prior myelosuppressive chemotherapy ( 4 week nitrosourea ) recover See Disease Characteristics Recovered prior radiotherapy No concurrent medication would interact study drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>